EUCTR2016-000925-38-GB进行中（未招募）1 期
GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding Factor VIII-V3 - Gene therapy for Haemophilia A; version 1
niversity College London (UCL)0 个研究点目标入组 18 人开始时间: 2016年12月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •i.Adult males, aged 18 years or over, with a confirmed diagnosis of severe Haemophilia A defined as baseline plasma FVIII levels of <1% of normal as assessed by a validated one-stage clotting assay or a chromogenic assay, resulting from for example intron 22 inversions, intron 1 inversions, splice-site mutations, small deletions/insertions, duplications and missense mutations.
- •ii.A severe bleeding phenotype as defined by at least one of the following:
- •a)On prophylaxis for a history of bleeding, or
- •b)On demand therapy with a current or past history of 4 or more bleeding episodes/year, or
- •c)Evidence of chronic haemophilic arthropathy (pain, joint destruction, and loss of range of motion);
- •iii.Received treatment with human FVIII concentrates with at least > 50 exposure days;
- •iv.Able to give full informed consent and able to comply with all requirements of the trial including 5-year long-term follow-up;
- •v.Willing to practice barrier contraception after vector administration until at least three consecutive semen samples are below the sensitivity of the assay for vector sequences (may be for 2-3 months);
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •I.Presence of neutralising anti-hFVIII antibodies (inhibitor, determined by the Bethesda inhibitor assay) at the time of enrolment or a previous history of hFVIII inhibitor;
- •II.Severe haemophilia A patients with large deletions (multiple exons) and nonsense mutations of the F8 gene.
- •III.Use of investigational therapy for haemophilia within 30 days before enrolment;
- •IV.Subjects with active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively or currently on antiviral therapy for hepatitis B or C. (Negative viral assays in two samples, collected at least six months apart, will be required to be considered negative. Both natural clearers and those who have cleared HCV on antiviral therapy are eligible).
- •V.Serological evidence of HIV.
- •VI.Evidence of liver dysfunction (persistently elevated ALT >1.5X upper limit of normal);
- •VII.Uncontrolled glaucoma, diabetes mellitus, or hypertension;
- •VIII.Any disease or condition (including cancer) at the physician's discretion that would prevent the patient from fully complying with the requirements of the study;
- •IX.Suspicious Lung lesions on CT scan that raise the possibility of cancer or premalignant pathology (based on chest CT scan done at screening or within 6 months prior to the screening visit);
- •X.Presence of liver abnormality that is suspicious of malignancy on screening liver ultrasound
- •XI.Patients with uncontrolled cardiac failure or unstable angina;
- •XII.Detectable neutralising anti-AAV8 antibodies
- •XIII.Received an AAV vector, or any other gene transfer agent in the previous 6 months
- •XIV.History of active tuberculosis, fungal disease or other chronic infection
- •XV.Subjects who are unwilling to provide the required semen samples
- •XVI.Poor performance status (WHO score >1)
- •XVII.Previous history or family history of venous or arterial thromboembolism
- •XXIII.Patients with a CHA2DS2-VASc score of 2 and above
研究者
相似试验
进行中（未招募）
1 期
Gene Therapy for Haemophilia A.Hemophilia ANCT03001830University College, London14
已完成
1 期
Gene therapy for Haemophilia ACTRI/2022/03/041304Centre for stem cell Research A Unit of inStem Bengaluru6
尚未招募
1 期
Lentiviral FVIII Gene TherapyHemophilia ANCT03217032Shenzhen Geno-Immune Medical Institute10
已完成
3 期
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the BloodTreatment of BleedingProphylaxis of BleedingChildrenHemophilia ANCT05147662Bayer36
已完成
1 期
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia AHemophilia ANCT05265767Christian Medical College, Vellore, India6